- Home
- ILAG vs MBIO Comparison
ILAG vs MBIO Comparison
Compare ILAG & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILAG
- MBIO
- Stock Information
- Founded
- ILAG 1981
- MBIO 2015
- Country
- ILAG Hong Kong
- MBIO United States
- Employees
- ILAG N/A
- MBIO N/A
- Industry
- ILAG Office Equipment/Supplies/Services
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ILAG Consumer Discretionary
- MBIO Health Care
- Exchange
- ILAG Nasdaq
- MBIO Nasdaq
- Market Cap
- ILAG 7.2M
- MBIO 7.3M
- IPO Year
- ILAG 2022
- MBIO N/A
- Fundamental
- Price
- ILAG $0.39
- MBIO $1.13
- Analyst Decision
- ILAG
- MBIO Strong Buy
- Analyst Count
- ILAG 0
- MBIO 1
- Target Price
- ILAG N/A
- MBIO $100.00
- AVG Volume (30 Days)
- ILAG 2.7M
- MBIO 1.1M
- Earning Date
- ILAG 05-27-2025
- MBIO 05-20-2025
- Dividend Yield
- ILAG N/A
- MBIO N/A
- EPS Growth
- ILAG N/A
- MBIO N/A
- EPS
- ILAG N/A
- MBIO N/A
- Revenue
- ILAG $7,506,551.00
- MBIO N/A
- Revenue This Year
- ILAG N/A
- MBIO N/A
- Revenue Next Year
- ILAG N/A
- MBIO N/A
- P/E Ratio
- ILAG N/A
- MBIO N/A
- Revenue Growth
- ILAG 16.50
- MBIO N/A
- 52 Week Low
- ILAG $0.35
- MBIO $1.01
- 52 Week High
- ILAG $1.35
- MBIO $65.00
- Technical
- Relative Strength Index (RSI)
- ILAG 48.98
- MBIO 37.64
- Support Level
- ILAG $0.34
- MBIO $1.07
- Resistance Level
- ILAG $0.98
- MBIO $1.22
- Average True Range (ATR)
- ILAG 0.08
- MBIO 0.07
- MACD
- ILAG 0.00
- MBIO 0.02
- Stochastic Oscillator
- ILAG 7.81
- MBIO 57.14
About ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc is engaged in the business of manufacturing and selling mechanical locksets. The business is spread across the Unites States, Canada, Australia, and China. Majority of the revenue is generated from the United States.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.